elsulfavirine elsulfavirine elsulfavirine (trade name elpida; also known as vm 1500) is drug used to treat hiv infection. it is a non-nucleoside reverse transcriptase inhibitor (nnrti). elsulfavirine is a prodrug which is metabolized to the active antiviral agent deselsulfavirine (also known as vm 1500a). it was developed by the russian company viriom. elsulfavirineclinical datatrade nameselpidaother namesvm 1500; elpivirinelegal statuslegal status rx-only in russia identifiers iupac name n-acetyl]amino]-3-chlorophenyl]sulfonylpropanamide cas number868046-19-9pubchem cid11527519drugbank14929uniizc4cgo0rugchemical and physical dataformulac24h17brcl2fn3o5smolar mass629.28 g·mol−1 inchi inchi=1s/c24h17brcl2fn3o5s/c1-2-21(32)31-37(34,35)17-4-6-20(19(27)11-17)30-22(33)9-14-3-5-18(25)24(23(14)28)36-16-8-13(12-29)7-15(26)10-16/h3-8,10-11h,2,9h2,1h3,(h,30,33)(h,31,32)key:ultdearcbrnrgr-uhfffaoysa-n in june 2017, elsulfavirine was approved for use in russia as an oral formulation for the treatment of hiv-1 infections in combination with other antiretroviral drugs. currently, elsulfavirine is used in antiretroviral therapy regimens in the russian federation, which includes the combination elsulfavirine + lamivudine (or emtricitabine) + tenofovir. long-acting injectable formulations of eslulfavarinin and deselsulfavarine are under investigation. in addition, roche is investigating the use of elsulfavirin for the treatment of covid-19 and it is currently in phase ii clinical trials for this possible indication.